- Home
- GRNT vs HQL Comparison
GRNT vs HQL Comparison
Compare GRNT & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GRNT | HQL |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Investment Managers |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.7M | 689.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | GRNT | HQL |
|---|---|---|
| Price | $5.03 | $21.53 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 800.2K | 154.5K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | 7.36% | ★ 11.56% |
| EPS Growth | ★ 28.57 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $450,306,000.00 | N/A |
| Revenue This Year | $18.12 | N/A |
| Revenue Next Year | $13.12 | N/A |
| P/E Ratio | ★ N/A | $27.25 |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $4.18 | $13.82 |
| 52 Week High | $6.15 | $22.67 |
Technical Indicators
Market Signals| Indicator | GRNT | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 57.98 |
| Support Level | $4.83 | $16.23 |
| Resistance Level | $5.05 | $22.67 |
| Average True Range (ATR) | 0.14 | 0.43 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 28.13 | 44.84 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.